U.S. advisers reject new use for J/Bayer’s Xarelto

<p>SILVER SPRING, Maryland (Reuters) U.S. advisers endorsed opposite expanding a use of Johnson Johnsons blood thinner Xarelto as a approach to revoke a risk of new heart attacks and strokes in people with heart problems.
A row of outward experts to a Food and Drug Administration voted on Wednesday that a tablet should not be authorized for people with acute coronary syndrome. JJ grown a drug in partnership with German drugmaker Bayer AG.
Xarelto is already authorized for use to revoke a risk of blood clots in a legs and lungs of people who have had knee or hip deputy surgery. It is also authorized to forestall strokes among people with a form of strange heartbeat called atrial fibrillation.
But a companies wanted to enhance a use to provide strident coronary syndrome, that refers to people who have heart attacks or chest pain, customarily given of a blocked coronary artery. About 1 million people in a United States are hospitalized any...